Details of the Drug

General Information of Drug (ID: DMXGE3O)

Drug Name
SAR408701
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 3 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
D05TBQ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 6.68E-91 0.29 1.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04154956) SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.